Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is one important treatment option for patients with aggressive adult T-cell leukemia/lymphoma (ATLL). Mogamulizumab (anti-CCR4 monoclonal antibody; Mog) was recently approved as a treatment for ATLL in Japan. Major concerns exist about t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical oncology 2016-10, Vol.34 (28), p.3426-3433
Hauptverfasser: Fuji, Shigeo, Inoue, Yoshitaka, Utsunomiya, Atae, Moriuchi, Yukiyoshi, Uchimaru, Kaoru, Choi, Ilseung, Otsuka, Eiichi, Henzan, Hideho, Kato, Koji, Tomoyose, Takeaki, Yamamoto, Hisashi, Kurosawa, Saiko, Matsuoka, Ken-Ichi, Yamaguchi, Takuhiro, Fukuda, Takahiro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!